Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: A randomized 26-week study on glycemic control and hypoglycemia

Diabetes Care

Volumn 34, Issue 3, 2011, Pages 604-606

  Gallwitz, Baptist ^a   Böhmer, Michael ^b   Segiet, Thomas ^c   Mölle, Andrea ^d   Milek, Karsten ^e   Becker, Bernd ^f   Helsberg, Karin ^g   Petto, Helmut ^h   Peters, Natalie ^g   Bachmann, Oliver ^g  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b Practice for Diabetology ^*  (Germany)

^c Practice for Diabetology   (Germany)

^d Practice for Angiology and Diabetology   (Germany)

^e Center of Diabetology   (Germany)

^f Joint Practice Partner der Gesundheit   (Germany)

^g LILLY DEUTSCHLAND GMBH   (Germany)

^h ELI LILLY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; HEMOGLOBIN A1C; INSULIN ASPART; METFORMIN;

ADULT; ARTICLE; BACKACHE; BODY WEIGHT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC PATIENT; DIARRHEA; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; DYSPEPSIA; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK ASSESSMENT; SIDE EFFECT; VOMITING; WEIGHT CONTROL; WEIGHT GAIN;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN ASPART; METFORMIN; MIDDLE AGED; PEPTIDES; TREATMENT OUTCOME; VENOMS;

EID: 79956151964     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc10-1900     Document Type: Article

References (13)

1. Matthaei S, Bierwirth R, Fritsche A, et al.; German Diabetes Association. Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association. Exp Clin Endocrinol Diabetes 2009;117:522-557
2. American Diabetes Association. Standards of medical care in diabetes - 2008 (Position Statement). Diabetes Care 2008;31(Suppl. 1):S12-S54
3. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559 (Pubitemid 351831356)
4. Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 2009;32:187-192
5. Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010;340:b4909
6. American Diabetes Association. Standards of medical care in diabetes - 2010 (Position Statement). Diabetes Care 2010;33(Suppl. 1):S11-S61
7. Gallwitz B, Böhmer M, Segiet T, et al. Exenatide vs. insulin aspart in patients with type 2 diabetes: results of a randomised, open-label study (Abstract). 45th Annual Meeting of the European Association for the Studies of Diabetes (EASD), 20-24 September 2010, Stockholm, Sweden. Available from http://www.easd.org
8. Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005;28:1245-1249
9. Nauck MA, Duran S, Kim D, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007;50:259-267
10. Bergenstal R, Lewin A, Bailey T, Chang D, Gylvin T, Roberts V; NovoLog Mix vs.-Exenatide Study Group. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea. Curr Med Res Opin 2009;25:65-75
11. Home PD. Comment on: Nauck MA, Duran S, Kim D, et al. (2007) A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a noninferiority study. Diabetologia 50:259-267. Diabetologia 2007;50:1561-1562; author reply 1563-1564
12. Esposito K, Ciotola M, Maiorino MI, et al. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial. Ann Intern Med 2008;149:531-539
13. Fogelfeld L, Dharmalingam M, Robling K, Jones C, Swanson D, Jacober S. A randomized, treat-to-target trial comparing insulin lispro protamine suspension and insulin detemir in insulin-naive patients with type 2 diabetes. Diabet Med 2010;27:181-188